Novanta (NASDAQ:NOVT) Releases Q2 2026 Earnings Guidance

Novanta (NASDAQ:NOVT) issued an update on its second quarter 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.810-0.860 for the period, compared to the consensus estimate of 0.860. The company issued revenue guidance of $259.0 million-$264.0 million, compared to the consensus revenue estimate of $256.9 million. Novanta also updated its FY 2026 guidance to 3.500-3.650 EPS.

Novanta Stock Performance

Shares of NASDAQ:NOVT opened at $159.19 on Wednesday. The firm has a market cap of $5.67 billion, a PE ratio of 115.36 and a beta of 1.62. The firm’s 50 day simple moving average is $126.50 and its 200-day simple moving average is $125.75. Novanta has a one year low of $98.27 and a one year high of $163.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.80 and a current ratio of 3.69.

Novanta (NASDAQ:NOVT) last issued its earnings results on Monday, May 11th. The technology company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.03. The business had revenue of $257.71 million for the quarter, compared to analyst estimates of $253.40 million. Novanta had a net margin of 5.35% and a return on equity of 13.11%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company posted $0.74 earnings per share. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q2 2026 guidance at 0.810-0.860 EPS. As a group, equities analysts predict that Novanta will post 3.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NOVT shares. Zacks Research raised shares of Novanta from a “strong sell” rating to a “hold” rating in a research report on Friday, January 16th. Wall Street Zen lowered shares of Novanta from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Robert W. Baird raised shares of Novanta from a “neutral” rating to an “outperform” rating and reduced their target price for the stock from $150.00 to $144.00 in a research report on Monday, March 30th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Novanta in a research report on Friday, April 17th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Novanta currently has an average rating of “Hold” and a consensus price target of $144.00.

Insider Buying and Selling

In other news, CEO Matthijs Glastra sold 6,500 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $130.05, for a total transaction of $845,325.00. Following the transaction, the chief executive officer directly owned 56,761 shares in the company, valued at approximately $7,381,768.05. This trade represents a 10.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Robert Buckley sold 9,957 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $116.77, for a total value of $1,162,678.89. Following the sale, the chief financial officer directly owned 96,616 shares in the company, valued at approximately $11,281,850.32. The trade was a 9.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 17,880 shares of company stock worth $2,208,476. Insiders own 1.20% of the company’s stock.

More Novanta News

Here are the key news stories impacting Novanta this week:

• Positive Sentiment: First-quarter revenue increased 10% year over year to $257.7 million, ahead of estimates, signaling healthy demand across Novanta’s medical and advanced technology end markets. Novanta Announces Financial Results for the First Quarter 2026
• Positive Sentiment: Adjusted diluted EPS came in at $0.81, topping consensus of $0.78, while adjusted EBITDA rose 14% to $57 million, reinforcing improved profitability. Novanta (NOVT) Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management’s second-quarter revenue guidance of $259 million to $264 million was above analyst expectations, suggesting momentum may continue into the next quarter. Novanta (NASDAQ:NOVT) Surprises With Q1 CY2026 Sales
• Neutral Sentiment: Full-year 2026 guidance for EPS of $3.50 to $3.65 was roughly in line with the consensus range, while revenue guidance of $1.0 billion to $1.1 billion matched broad expectations. Novanta Inc. (NOVT) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: GAAP diluted EPS was $0.51 versus $0.50 a year ago, but operating income declined to $27.5 million from $32.4 million, a mixed signal that offsets some of the earnings beat. Novanta Announces Financial Results for the First Quarter 2026

Institutional Investors Weigh In On Novanta

Institutional investors have recently bought and sold shares of the company. Danske Bank A S acquired a new stake in Novanta in the third quarter valued at approximately $40,000. Van ECK Associates Corp boosted its stake in Novanta by 17.2% in the third quarter. Van ECK Associates Corp now owns 1,627 shares of the technology company’s stock valued at $163,000 after acquiring an additional 239 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in Novanta in the fourth quarter valued at approximately $219,000. EntryPoint Capital LLC acquired a new stake in Novanta in the fourth quarter valued at approximately $261,000. Finally, Corient Private Wealth LLC acquired a new stake in Novanta in the fourth quarter valued at approximately $275,000. 98.35% of the stock is currently owned by institutional investors and hedge funds.

Novanta Company Profile

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.